MONROVIA, Liberia — Africans seeking a drug to help contain the Ebola virus will have to wait months before a potentially life-saving experimental treatment used on two infected Americans is produced even in small amounts, officials said.
And there are no guarantees that the medication known as ZMapp would help curb the spread of the dreaded disease, which starts with a fever and body aches and sometimes progresses to serious bleeding. Supplies of the drug are limited. It has never been tested for safety or effectiveness in humans.
The health minister of Nigeria, one of the four countries where Ebola has broken out, told a news conference in his country that he had asked the U.S. Centers for Disease Control and Prevention about access to the drug. A CDC spokesman said Wednesday "there are virtually no doses available."
Some people in other affected countries questioned why the medicine has not been offered to infected Africans.
Anthony Kamara, a 27-year-old man riding a bicycle in Freetown, Sierra Leone, said "Americans are very selfish. They only care about the lives of themselves and no one else."
He referred to ZMapp as "the miracle serum" that the U.S. has "refused to share with us to save African lives."
The lack of wider availability "shows simply that white patients and black patients do not have the same value in the eyes of world medicine," said Nouridine Sow, a sociology professor at the Universal Institute of Guinea.
But testing an unproven drug on a large population carries risks. Earlier this week, the CDC director emphasized that it's impossible to know whether ZMapp helped the sick American aid workers.
"Until we do a study, we don't know if it helps, if it hurts or if it doesn't make any difference," Tom Frieden told a health symposium in Kentucky.
The outbreak first emerged in Guinea and spread to neighboring Sierra Leone and Liberia before reaching Nigeria. Almost 1,000 people have died since March.